Form 4: PepGen CFO's Stock Options Repriced to $4.53

PepGen Inc.'s Chief Financial Officer, Noel Donnelly, had outstanding stock options repriced to an exercise price of $4.53 per share, effective November 4, 2025.

Summary

• PepGen Inc.'s Chief Financial Officer, Noel Donnelly, had a total of 660,376 outstanding stock options repriced on November 4, 2025.
• The exercise price for these options was reduced to $4.53 per share from previous prices ranging from $10.88 to $16.62.
• The repricing was approved by the Issuer's Board of Directors and applies to options granted under the 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan.
• The reduced exercise price is contingent upon the Reporting Person satisfying an applicable retention period; otherwise, the original exercise price will apply.
• The transactions are exempt under SEC Rules 16b-6(d) and 16b-3.
• The options vest over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remainder in 36 equal monthly installments, subject to continued service.

Sentiment

Score: 4

Explanation: The repricing of options is a mixed signal. While it aims to re-incentivize a key executive, it inherently acknowledges a significant decline in the company's stock price, which is a negative indicator. The benefit to the executive is clear, but for existing shareholders, it suggests past underperformance and potential future dilution.

Positives

• The Chief Financial Officer, Noel Donnelly, benefits from a significantly lower exercise price of $4.53 for 660,376 stock options, enhancing their potential value and incentive.
• The repricing aims to restore the incentive value of previously underwater options, potentially improving executive retention and motivation.

Negatives

• The need for option repricing suggests that PepGen Inc.'s stock price has significantly declined since the original grant dates, making previous options less valuable.
• While beneficial for the executive, repricing can be viewed negatively by existing shareholders as it effectively grants new options at a lower price, potentially increasing future dilution if the stock recovers.

Risks

• The repricing implies a risk of continued low stock performance, as the company felt the need to adjust option prices to maintain executive incentives.
• Failure of the Reporting Person to satisfy the applicable retention period would result in the original, higher exercise prices applying, negating the benefit of the repricing.

Future Outlook

The repriced options are subject to vesting schedules, with 25% vesting on the one-year anniversary of the grant date (or vesting commencement date) and the remainder vesting in 36 equal monthly installments, contingent on continued service. This structure aims to incentivize long-term retention of the Chief Financial Officer.

Management Comments

• On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan.
• The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply.

Industry Context

Stock option repricing is a common practice in the biotechnology and pharmaceutical sectors, particularly when a company's stock price has experienced a significant decline, rendering previously granted options 'underwater' (i.e., the exercise price is higher than the current market price). This action is typically taken to restore the incentive value of equity awards, retain key executives, and motivate them to drive future stock price appreciation. It reflects a challenging period for the company's stock performance relative to prior expectations.

Comparison to Industry Standards

• Option repricing is a known mechanism used by companies, especially in volatile sectors like biotech, to re-align executive incentives when stock prices fall significantly. For example, companies like Biogen or Moderna have faced periods where stock performance led to similar considerations for executive compensation.
• The condition of a 'retention period' for the reduced price is a standard practice to ensure the executive remains with the company and earns the benefit, similar to how other companies structure performance-based or time-based vesting.
• The vesting schedule of 25% on the first anniversary and monthly thereafter is a common industry standard for executive equity grants, aiming for long-term retention.

Corporate Governance

Related Party Transactions

• The repricing of stock options for Noel Donnelly, the Chief Financial Officer, constitutes a related party transaction as it involves an equity award modification between the company and a key executive.

Stakeholder Impact

• Shareholders: May view the repricing negatively as it reflects past stock underperformance and could lead to increased dilution if the stock price recovers, as more options become 'in-the-money' at a lower threshold.
• Employees (Executive): Noel Donnelly directly benefits from the repricing, as it restores the incentive value of his equity awards, potentially increasing his motivation and retention.
• Company: Aims to retain a key executive and re-align incentives, which could positively impact future performance if the executive is motivated to drive stock price appreciation.

Next Steps

• Noel Donnelly must satisfy the applicable retention period to benefit from the reduced exercise price of $4.53.
• The repriced stock options will continue to vest according to their original schedules, subject to continued service.

Key Dates

Recommendation

This Form 4 primarily details an executive compensation adjustment (stock option repricing) in response to past stock performance. While it re-incentivizes a key executive, it doesn't provide new fundamental financial data or strategic shifts that would warrant a strong buy or sell recommendation. The repricing itself suggests the stock has underperformed, but the action aims to stabilize executive incentives. Investors should hold and await more comprehensive financial reports or strategic updates to assess the company's future prospects.

Keywords

PepGen Inc., PEPG, Stock Options, Option Repricing, Chief Financial Officer, Noel Donnelly, SEC Form 4, Executive Compensation, Equity Incentive Plans, Corporate Governance